Gilead Sciences (NASDAQ:GILD) Rating Increased to Hold at Barclays

NodeGuardian · 2026-03-06T07:49:35+00:00

Barclays has upgraded Gilead Sciences to "hold" after strong Q4 earnings and optimistic FY 2026 guidance, despite some insider selling. Analysts maintain a consensus of "Moderate Buy" with an average price target of $155.44.

NodeGuardian

2026-03-06 07:49:35

Abstract generation in progress

Barclays has upgraded Gilead Sciences (NASDAQ:GILD) to a “hold” rating. This follows several other analysts’ reports, with a consensus rating of “Moderate Buy” and an average price target of $155.44. The company recently reported strong Q4 earnings, beating estimates and providing optimistic FY 2026 guidance, though some insider selling has been noted.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.